{"id":"NCT04678856","sponsor":"Sanofi","briefTitle":"Dupilumab in CRSsNP","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-02","primaryCompletion":"2023-11-14","completion":"2024-01-29","firstPosted":"2020-12-22","resultsPosted":"2024-12-18","lastUpdate":"2025-02-10"},"enrollment":71,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Rhinosinusitis Without Nasal Polyps","Sinusitis","Chronic Sinusitis","Sinus Disorder","Respiratory Disorder"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part A and B: Dupilumab","type":"EXPERIMENTAL"},{"label":"Part A and B: Matching placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only\n\nSecondary Objectives:\n\n* To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on CT scan and sinus total symptom score (sTSS) compared to placebo\n* To evaluate the safety and tolerability of dupilumab in CRSsNP patients compared to placebo\n* To evaluate the pharmacokinetics (PK) of dupilumab in CRSsNP patients compared to placebo\n* Assessment of immunogenicity to dupilumab over time compared to placebo","primaryOutcome":{"measure":"Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab Group","timeFrame":"Baseline (Day 1) and Week 24","effectByArm":[{"arm":"Dupilumab 300 mg q2w","deltaMin":-6.63,"sd":3.91}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":21},"locations":{"siteCount":58,"countries":["United States","Argentina","Belgium","Canada","Chile","China","Hungary","Portugal","Russia","South Korea","Spain","Sweden","Ukraine"]},"refs":{"pmids":[],"seeAlso":["https://sanofi.trialsummaries.com/Study/StudyDetails?id=25252&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":33},"commonTop":["Covid-19","Injection Site Erythema","Accidental Overdose","Injection Site Reaction","Nasopharyngitis"]}}